Prognostic significance of pretreatment lymphocyte/monocyte ratio in retroperitoneal liposarcoma patients after radical resection
Received 19 April 2018
Accepted for publication 9 August 2018
Published 18 October 2018 Volume 2018:10 Pages 4727—4734
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 3
Editor who approved publication: Professor Lu-Zhe Sun
Peng Luo,1,2 Weiluo Cai,1,2 Lingge Yang,1,2 Shiqi Chen,1,2 Zhiqiang Wu,1,2 Yong Chen,1,2 Ruming Zhang,1,2 Yingqiang Shi,1,2 Wangjun Yan,1,2 Chunmeng Wang1,2
1Department of Bone and Soft Tissue Sarcomas, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
Background: The aim of this study was to evaluate the prognostic value of pretreatment inflammatory biomarkers in retroperitoneal liposarcoma (RPLS) patients after radical resection.
Patients and methods: One hundred patients with RPLS who underwent radical resection between September 2004 and October 2010 at Fudan University Shanghai Cancer Center were included in this study. Laboratory tests of peripheral blood were sampled before surgery. The optimal cutoff values of systemic inflammatory markers were defined by receiver-operating curve analyses. Curves of disease-free survival (DFS) and overall survival (OS) were obtained by the Kaplan–Meier method. Cox proportional hazards regression modeling was used to perform univariate and multivariate analyses.
Results: The median follow-up time was 53 months. The median DFS and OS were 27 and 86 months, respectively. On the basis of the optimal cutoff value of 3, 24 patients were classified into low lymphocyte/monocyte ratio (LMR) group and 76 patients into high LMR group. In univariate analysis, low LMR group had significantly shorter DFS (P<0.001) and OS (P<0.001) compared to high LMR group. In multivariate analysis, low LMR was demonstrated as an independent negative prognostic factor for both DFS (HR=2.854, 95% CI=1.392–5.851, P=0.004) and OS (HR=3.897, 95% CI=1.681–9.033, P=0.002).
Conclusion: Pretreatment LMR is a useful prognostic marker in RPLS patients after radical resection.
Keywords: retroperitoneal liposarcoma, inflammatory biomarkers, prognosis, lymphocyte, monocyte ratio
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]